Dive Brief:Brain drug developers Supernus and Indivior on Monday announced plans to merge, bringing together two companies specializing in drugs for central nervous system disorders that had combined revenues of $2 billion in 2025. After the close, the former Individor shareholders will own around 57% of the combined company and Supernus’ will own around 43%. Following the close, the company will be called Supernus, headquartered at Supernus’ Rockville, Maryland offices, and will be headed by its current CEO, Jack Khattar. The biggest seller is Indivior’s Sublocade, a long-acting injection that treats opioid-use disorder, and its only drug recording sales growth in 2025 as it shifts away from the oral products that have led to legal problems. The overall revenue growth that Supernus did see in 2025 was purchased with its $561 million acquisition of Sage Therapeutics.